BPC-157: Complete Research Guide and Protocol Overview

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It is derived from a protective protein found in human gastric juice. BPC-157 has been one of the most extensively studied research peptides in preclinical literature, with over 100 published studies examining its effects in animal models. The peptide has a molecular weight of approximately 1,419 Da and the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is important to note that BPC-157 is NOT FDA approved for any human therapeutic use. All research findings discussed here come from preclinical (animal) studies and should be interpreted accordingly.

The majority of BPC-157 research has been conducted in rodent models. Studies have examined the peptide's effects on various tissue types including tendons (PMID: 21030672), muscles (PMID: 30915550), the gastrointestinal tract (PMID: 14974589), and blood vessels. The proposed mechanism involves upregulation of growth factor expression, particularly VEGF (vascular endothelial growth factor) and the FAK-paxillin pathway, which are involved in tissue repair signaling. A 2018 systematic review (PMID: 30915550) compiled the preclinical evidence and noted consistent results across multiple tissue types in animal models. However, the review also emphasized the absence of human clinical trials, making it premature to draw conclusions about human applications.

One of BPC-157's notable characteristics in research is its reported stability when administered orally, which is unusual for peptides. Most peptides are rapidly degraded by digestive enzymes and have negligible oral bioavailability. BPC-157's partial origin from a gastric protein may contribute to some degree of acid stability, though the exact oral bioavailability in humans has not been established in clinical trials. In preclinical studies, both oral and subcutaneous (injection) administration have shown activity, though the bioavailability profiles differ significantly. Subcutaneous injection provides more direct systemic delivery, while oral administration must survive the GI tract. Many research protocols use subcutaneous injection for more predictable dosing, while oral administration is studied for gastrointestinal-targeted applications.

BPC-157's precise half-life in humans has not been established through clinical pharmacokinetic studies. Based on available preclinical data and its molecular characteristics, estimates range from approximately 4 hours for the injectable form. This relatively short half-life explains why research protocols typically involve twice-daily administration. The peptide requires reconstitution from lyophilized powder using bacteriostatic water before subcutaneous injection. Standard reconstitution volumes and techniques apply — use the reconstitution guide for detailed calculation instructions. The peptide should be stored refrigerated after reconstitution and protected from light.

In published preclinical studies, BPC-157 doses have typically ranged from 1-10 mcg/kg in animal models. It is critical to emphasize that these are animal research doses and cannot be directly extrapolated to humans without proper clinical trials. The peptide is typically administered once or twice daily in research settings, consistent with its estimated half-life. Common injection sites reported in research documentation include the abdomen (subcutaneous) and areas local to the tissue of interest. Protocol durations in published studies range from a few days to several weeks depending on the endpoint being studied. Any human use should only occur under the supervision of a qualified healthcare provider.

While preclinical studies have generally reported favorable safety profiles with minimal adverse effects observed in animal models, the absence of human clinical trials means the safety profile in humans is not established. No FDA-approved drug contains BPC-157, and no clinical trials in humans have been completed to establish safe dosage ranges, contraindications, or drug interactions for human use. Sourcing is also a significant concern — without pharmaceutical-grade manufacturing standards required for FDA-approved drugs, the purity and identity of commercially available research peptides can vary between suppliers. Third-party testing (such as HPLC purity analysis and mass spectrometry verification) is recommended for any research-grade peptide.

Dosed supports BPC-157 protocol tracking with features designed for its specific characteristics. The app includes twice-daily reminder scheduling aligned with the peptide's estimated half-life, injection site rotation tracking with a visual body map, reconstitution calculator for accurate BAC water and dosing calculations, and half-life visualization showing estimated active levels over time. You can also log batch numbers and vendor information for research documentation purposes, and export your complete protocol history for record-keeping.